Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats HIV-1 infection. ANDA 208890, held by Amneal. Ritonavir.
As of Nov 15, 2026, ANDA 208890 (Ritonavir), held by Amneal, was first approved by FDA on Sep 17, 2018, with 0 approved supplements and 0 published complete response letters.
First approved: Sep 17, 2018
Review: Standard
Supplements approved: 0
Complete response letters: 0
What It's For
From the FDA-approved label (Indications and Usage)
Ritonavir tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters
